H.C. Wainwright Keeps a Buy Rating on Trillium Therapeutics

In a report released today, Swayampakula Ramakanth from H.C. Wainwright reiterated a Buy rating on Trillium Therapeutics (NASDAQ: TRIL), with a price target of $10. The company’s shares closed on Friday at $6.60.

According to TipRanks.com, Ramakanth is a 4-star analyst with an average return of 5.3% and a 39.8% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Diffusion Pharmaceuticals Inc, Eleven Biotherapeutics, and IntelGenx Technologies.

Trillium Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $8.50.

See today’s analyst top recommended stocks >>

The company has a one-year high of $13.30 and a one-year low of $4.15. Currently, Trillium Therapeutics has an average volume of 62.74K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Trillium Therapeutics Inc. is a clinical stage immuno-oncology company, which engages in the development of innovative therapies for the treatment of cancer. Its pipeline is comprised of TTI-621, TTI-622, and TTI-2341(EGFR Inhibitor). The company was founded on March 31, 2004 and is headquartered in Toronto, Canada.